Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
CD19 inhib
Welcome,
Profile
Billing
Logout
70 Companies
66 Products
66 Products
55 Diseases
293 Trials
7328 News
All trials
Active industry trials
Active owner-sponsored trials
Active trials
Export
Download options
Which format:
PDF
Excel Chart
TSV
Phase
N/A
1
2
3
4
Trials
0
18
36
54
72
90
108
126
144
162
180
Blincyto
(blinatumomab) / Astellas, Amgen
Monjuvi
(tafasitamab-cxix) / Incyte
Uplizna
(inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
obexelimab
(ZB012) / Zenas BioPharma
KN5501
/ Rui Therapeutics
emfizatamab
(GNC-038) / Biokin Pharma
budoprutug
(TNT119) / Climb Bio
surovatamig
(AZD0486) / AstraZeneca
CB CAR-NK019
/ Zhejiang University
SNC103
/ Shanghai Simnova Bio
CD19.t-haNK
/ ImmunityBio
CLN-978
/ Cullinan Therap
MK-1045
/ Merck (MSD)
NKX019
/ Nkarta Therap
PIT565
/ Novartis
A-319
/ ITabMed
ET-190
/ Eureka Therap
FT596
/ Fate Therap
AFM11
/ Affimed
CNTY-101
/ Century Therap
Combotox
(Imtox19/Imtox22) / Montefiore Medical Center, National Cancer Institute, Abiogen
GSK5926371
/ GSK
MDX-1342
/ BMS
TAK-007
/ Takeda, UT MD Anderson Cancer Center
TG-1801
/ Light Chain Biosci, TG Therap
dualCAR-NK19/70
/ Zhejiang University
duvortuxizumab
(MGD011) / MacroGenics
AMG 562
/ Amgen
Anti-CD19 CAR NK Cells
/ Allife Medicine
CAR-NK-CD19 cells
/ Beijing Boren Hospital
FT522
/ Fate Therap
GNR-084
/ Generium
JD010
/ Beijing JD Biotech
PCAR-119
/ PersonGen Biomedicine
QN-019a
/ Qihan Biotech
RG6333
/ Roche
RGV004
/ Hangzhou Rongu Biotech
TAC01-CD19
/ Triumvira
TC-110
/ Adaptimmune
YT-19
/ BriSTAR Immunotech
YT-19/22
/ BriSTAR Immunotech
anti CD19/CD22 CAR NK cells
/ Allife Medicine
anti-CD19 iCAR NK cells
/ Allife Medicine
autologous TRAC locus-inserted CD19-STAR-T
/ Chinese PLA General Hospital
englumafusp alfa
(RG6076) / Roche
onCARlytics
(CF33-CD19) / Imugene
universal chimeric antigen receptor-modified AT19 cells
/ Wuhan Union Hospital, Chengdu USino Techno
yttrium Y 90 anti-CD19 Ab
(BU 12) / National Cancer Institute
